文献速递特殊人群用药

子宫肌瘤的当前与新兴治疗选择

Current and Emerging Treatment Options for Uterine Fibroids.
PubMed 文献 · Drugs · 2023-11-03

子宫肌瘤是育龄女性最常见的良性肿瘤,50岁前检出率可达80%,严重影响生活质量。现有药物通过阻断性激素对肌瘤生长的刺激起效,但妊娠禁忌且仅在使用期间有效。本文综述当前药物治疗的疗效与副作用,以及有前景的新兴天然化合物。

要点

  • 子宫肌瘤50岁前检出率可达80%,育龄女性最常见良性肿瘤。
  • 现有激素治疗阻断性激素刺激肌瘤生长,但妊娠禁忌且仅用药期间有效。
  • 亟需安全、持久且兼容生育的非手术治疗选择。

核心结论

  • 现有药物治疗有效但受限于妊娠禁忌和长期安全性,亟需安全、持久且兼容生育的非手术选择。

研究设计与样本

  • 综述文章,覆盖子宫肌瘤当前药物治疗的疗效与副作用及新兴天然化合物。

主要发现

  • 子宫肌瘤在50岁前检出率可达80%,并造成身体、情感、社会和经济负担及生活质量下降。
  • 根治性子宫切除术消除未来妊娠可能,保留子宫的手术和放射学替代方案与长期生殖功能下降和/或高肿瘤复发率相关。
  • 激素治疗通过阻断性腺类固醇激素对肌瘤生长的刺激作用起效,但妊娠禁忌且仅在使用期间有效。

临床怎么用

  • 药物治疗可限制月经过多等症状,但需考虑妊娠禁忌和长期安全性,仅用药期间有效。
  • 保留子宫的手术和放射学替代方案需权衡长期生殖功能下降和肿瘤复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Uterine fibroids are the most common benign neoplasm of the female reproductive tract in reproductive age women. Their prevalence is age dependent and can be detected in up to 80% of women by the age of 50 years. Patients affected by uterine fibroids may experience a significant physical, emotional, social, and financial toll as well as losses in their quality of life. Unfortunately, curative hysterectomy abolishes future pregnancy potential, while uterine-sparing surgical and radiologic alternatives are variously associated with reduced long-term reproductive function and/or high tumor recurrence rates. Recently, pharmacological treatment against uterine fibroids have been widely considered by patients to limit uterine fibroid-associated symptoms such as heavy menstrual bleeding. This hormonal therapy seemed effective through blocking the stimulatory effects of gonadal steroid hormones on uterine fibroid growth. However, they are contraindicated in women actively pursuing pregnancy and otherwise effective only during use, which is limited because of long-term safety and other concerns. Accordingly, there is an urgent unmet need for safe, durable, and fertility-compatible non-surgical treatment options for uterine fibroids. In this review article, we cover the current pharmacological treatments for uterine fibroids including their comparable efficacy and side effects as well as emerging safe natural compounds with promising anti-uterine fibroid effects.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Ali M, Ciebiera M, Wlodarczyk M, et al. Current and Emerging Treatment Options for Uterine Fibroids. Drugs. 2023. PMID: 37922098. doi:10.1007/s40265-023-01958-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。